Esomeprazole
- Generic Name
- Esomeprazole
- Brand Names
- Nexium, Vimovo, Nexium Control
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 119141-88-7
- Unique Ingredient Identifier
- N3PA6559FT
- Background
Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison ...
- Indication
Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions incl...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Upper Gastrointestinal Hemorrhage, Zollinger-Ellison Syndrome, Acute benign gastric ulcers, Develop NSAID-induced gastric ulcers, Maintenance of healing Erosive esophagitis, Postendoscopy Bleeding
- Associated Therapies
- -
PPI Sequencing Study
- Conditions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00384592
- Locations
- 🇬🇧
Research Site, Warminster, United Kingdom
🇬🇧Research SIte, Glasgow, United Kingdom
Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice
- Conditions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Target Recruit Count
- 150
- Registration Number
- NCT00363701
- Locations
- 🇩🇰
Department of gastroenterology, Glostrup University Hospital, Glostrup, Denmark
Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT00361985
- Locations
- 🇺🇸
Weill Medical College of Cornell Unversity, New York, New York, United States
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia
- Conditions
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 2513
- Registration Number
- NCT00357682
An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
- Conditions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00352261
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
🇺🇸Research SIte, Springfield, Missouri, United States
Symptom Adapted Therapy in GERD Patients
- Conditions
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 441
- Registration Number
- NCT00343161
- Locations
- 🇩🇪
Reseach Site, Urspringen, Germany
🇩🇪Research Site, Zwickau, Germany
AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 150
- Registration Number
- NCT00325715
Nexium RESPONSE Trial
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2009-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00318968
- Locations
- 🇩🇰
Research Site, Viby J, Denmark
PPI Test in GP Patients
- Conditions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2007-08-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00318084
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 961
- Registration Number
- NCT00317044
- Locations
- 🇨🇭
Research Site, Basel, Basel Stadt, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.